UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016444
Receipt number R000018275
Scientific Title A phase 2 study of first line low dose afatinib in advanced non-small-cell lung cancer patients with mutated epidermal growth factor receptor
Date of disclosure of the study information 2015/02/04
Last modified on 2019/03/26 22:54:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phase 2 study of first line low dose afatinib in advanced non-small-cell lung cancer patients with mutated epidermal growth factor receptor

Acronym

A phase 2 study of first line low dose afatinib in advanced non-small-cell lung cancer patients with mutated epidermal growth factor receptor

Scientific Title

A phase 2 study of first line low dose afatinib in advanced non-small-cell lung cancer patients with mutated epidermal growth factor receptor

Scientific Title:Acronym

A phase 2 study of first line low dose afatinib in advanced non-small-cell lung cancer patients with mutated epidermal growth factor receptor

Region

Japan


Condition

Condition

Non-small cell lung cancer

Classification by specialty

Medicine in general Pneumology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To investigate the efficacy and safety of low dose afatinib in patients with EGFR-mutant NSCLC: Exon19 deletion or Exon 21 L858R mutation.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Progression free survival

Key secondary outcomes

Overall survival
Safety
Response rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Afatinib is prescribed at 20mg/day daily. If tolerated, this dose can be increased after 21 days of treatment.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Histological or cytological proven NSCLC
2)With sensitive EGFR mutation: Exon 19 deletion or Exon 21 L858R mutation
3)No indication for operation or radiation therapy
4)Chemotherapy-naive advanced or relapsed NSCLC
5)If after adjuvant or neoadjuvant chemotherapy: No molecular target drug
4 weeks after treatment without platinum agent
6)interval of radiation therapy: 1 weeks after thoracic RT
7)age: over 20
8)ECOG PS: 0-2
9)Adequate organ functions judged by laboratory tests
10)Life expectanancy: over 3 months
11)Written informed consent

Key exclusion criteria

1)obvious interstitial pneumonia or pulmonary fibrosis by chest CT
2)uncontrolled pleural or pericardial effusion
3)symptomatic brain metastasis
4)active multiple tumor
5)cannot take orally
6)obvious liver cirrhosis
7)clinically significant heart disease
8)infection which requires treatment
9)pregnancy
10)history of severe allergic reaction
11)anticontraceptive
12)inadequate patients whom physicians considered

Target sample size

45


Research contact person

Name of lead principal investigator

1st name Yoshioka
Middle name
Last name Hiroshige

Organization

Kurashiki Central Hospital

Division name

Department of Respiratory Medicine

Zip code

710-8602

Address

1-1-1, Miwa, Kurashiki, Okayama

TEL

086-422-0210

Email

hirotin@kchnet.or.jp


Public contact

Name of contact person

1st name Toshihide
Middle name
Last name Yokoyama

Organization

Kurashiki Central Hospital

Division name

Department of Respiratory Medicine

Zip code

710-8602

Address

1-1-1, Miwa, Kurashiki, Okayama

TEL

086-422-0210

Homepage URL


Email

ty14401@kchnet.or.jp


Sponsor or person

Institute

Kyoto Thoracic Oncology Research Group (KTORG)

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kurashiki Central Hospital

Address

1-1-1, Miwa, Kurashiki, Okayama

Tel

086-422-0210

Email

igakuken@kchnet.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 02 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 01 Month 29 Day

Date of IRB

2015 Year 01 Month 29 Day

Anticipated trial start date

2015 Year 02 Month 05 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 02 Month 04 Day

Last modified on

2019 Year 03 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018275


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name